Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
about
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue SarcomaFollow-up in soft tissue sarcomasAutologous haematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: a Cochrane systematic review*Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus StatementSoft tissue sarcoma of the extremities: pending questions on surgery and radiotherapyWhat is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case seriesResponse to chemotherapy is not related to chromosome instability in synovial sarcoma.Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaThe pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study.Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?Retroperitoneal liposarcoma: current insights in diagnosis and treatmentWiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence.Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults.En-bloc resection of a giant retroperitoneal lipoma: a case report and review of the literature.A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatmentsPrognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma.Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomasPrognostic factors for elderly patients with primary malignant bone and soft tissue tumors.Retroperitoneal Sarcoma. Outcome Analysis in a Teaching Hospital in Eastern India- a Perspective.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03).Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services.Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcomaAdvanced chondrosarcomas: role of chemotherapy and survival.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin.Primary breast leiomyosarcoma.The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.How long should we follow patients with soft tissue sarcomas?Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model.How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.Liposarcoma of the spermatic cord masquerading as an inguinal hernia.
P2860
Q26741817-A47DB1FD-1CB9-4F5E-A3CE-8CA704CAB926Q26830942-75AC02CC-35FA-4628-95C7-B2E928D5E0BFQ26852687-938CF4CF-DAFA-4387-9996-714307D41092Q28069514-8CA36D58-D8A5-4A2E-960D-45EF28548DF5Q28076849-A4CD0B42-8E3E-4A74-93E9-D741FD5FA1EBQ33613689-76B7A9A1-0BED-44E3-BF88-05E796AE2977Q33671281-998B3B29-7F98-4245-A37D-DA035069D481Q33850011-1667DE9D-26E9-4FC1-9232-263D88006E19Q33912177-5052C90C-E304-4200-BB1E-005CDDCEB83DQ34314062-2C5C795C-1D5A-483A-A57A-0E59EAAA91ECQ34395325-28B1C779-CFAF-4458-A6C7-F2CA634DC929Q34637866-E4920A07-C775-4F4D-A000-A1B8DF638F7EQ34655297-CB6AB70B-052C-4772-896E-AFC8CF120DA1Q34670333-17FCF508-8ECF-4705-9B0C-ACFCC437F858Q35061368-D108AFFA-7C3A-4CD4-B4A2-65A3424E2FFBQ35066363-0E6DAE20-C55D-4CEF-B8F0-E9DC9EB3742EQ35133820-4FCCC93F-12BB-43A9-8A1A-9037C7C8150EQ35179978-6F4EDE5B-3D8E-4BC4-A491-5E946EA174CEQ35194716-E5074235-161D-490E-9B55-B3147ECC271AQ35427293-5074B64A-9278-4340-8529-40D4047A072EQ35677857-51A2AF07-EEDE-45FF-8BB4-AF456ABB450EQ35837348-66D1B853-1EB7-4F9E-9926-3B0A27BB7C7DQ35944531-01F2DA66-EE65-4C7C-A686-F060172D0511Q36079901-BC9133F4-2D94-4229-B714-48DC613D10F4Q36099606-2855C9EB-55B1-42F9-9390-B85CA35CBE11Q36269577-039854EE-8111-4431-8A32-F4C1312F787CQ36273285-B163C813-D7FE-4ADE-8B57-0F7BA706EC9FQ36573310-C2D3414D-C514-4BAB-83FE-BF353D1A5542Q36965629-BE4670E5-5AC5-4244-BD34-51407CFA8F1DQ37082346-7C9E5445-382D-4DF2-AE25-80E0C1F8CD0FQ37190323-8DA3A385-BFF2-4A9E-8B68-47E35C7CA531Q37265042-78F2DD9A-E09E-4E48-A2CE-800A66A1006CQ37330372-28EA2357-38AD-4F67-986C-EF9292A26563Q37388663-A6627AA1-646D-4536-8751-E37324600B03Q37435891-FAF68486-F1CF-46A8-AE5D-DC4C1A322D5CQ37502192-0438EFA7-762B-4D16-8C86-396DB587CA0EQ37563799-53D26715-ABC8-42E6-AA6C-91087158A60CQ37654201-D7B743A6-A872-4BB9-9680-CF308068513AQ37671153-DA81AA29-B009-482A-990C-8C2FF3608494Q38193095-239AF213-7493-4649-9EFA-D67D36CBCB64
P2860
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
description
im September 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2012
@uk
name
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@en
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@nl
type
label
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@en
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@nl
prefLabel
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@en
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@nl
P2860
P356
P1433
P1476
Soft tissue and visceral sarco ...... nosis, treatment and follow-up
@en
P2860
P304
vii92-vii99
P356
10.1093/ANNONC/MDS253
P433
P577
2012-09-20T00:00:00Z